Q2 2017 13F Holders as of 30 Jun 2017
-
Type / Class
-
Debt / NOTE 3.250%11/0
-
Market price (% of par)
-
135.04%
-
Total 13F principal
-
$212,644,000
-
Principal change
-
-$5,480,000
-
Total reported market value
-
$287,330,000
-
Number of holders
-
21
-
Value change
-
-$3,293,717
-
Number of buys
-
13
-
Number of sells
-
6
Institutional Holders of THERAVANCE BIOPHARMA INC - NOTE 3.250%11/0 as of Q2 2017
As of 30 Jun 2017,
THERAVANCE BIOPHARMA INC - NOTE 3.250%11/0 was held by
21 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$212,644,000
in principal (par value) of the bond.
The largest 10 bondholders included
LINDEN ADVISORS LP, BAUPOST GROUP LLC/MA, WOLVERINE ASSET MANAGEMENT LLC, CITADEL ADVISORS LLC, CSS LLC/IL, LAZARD ASSET MANAGEMENT LLC, Verition Fund Management LLC, FMR LLC, GEODE CAPITAL MANAGEMENT, LLC, and Context Capital Management, LLC.
This page lists
21
institutional bondholders reporting positions
for the Q2 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.